Telix Pharmaceuticals Lim...

NASDAQ: TLX · Real-Time Price · USD
17.59
0.19 (1.09%)
At close: May 01, 2025, 11:53 AM
1.09%
Bid 17.74
Market Cap 5.89B
Revenue (ttm) 24.45M
Net Income (ttm) -1.98M
EPS (ttm) 0.09
PE Ratio (ttm) 195.42
Forward PE n/a
Analyst Strong Buy
Ask 17.88
Volume 10,341
Avg. Volume (20D) 38,193
Open 17.86
Previous Close 17.40
Day's Range 17.59 - 18.15
52-Week Range 13.61 - 30.36
Beta 2.49

About TLX

Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibo...

Industry Biotechnology
Sector Healthcare
IPO Date Nov 14, 2024
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol TLX
Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for TLX stock is "Strong Buy." The 12-month stock price forecast is $22, which is an increase of 25.09% from the latest price.

Stock Forecasts
2 months ago
+12%
Telix Pharmaceuticals shares are trading higher af... Unlock content with Pro Subscription
3 months ago
+1.07%
Telix Pharmaceuticals shares are trading higher after the company announced it will buy the therapeutic pipeline, technology platform, and research facility from ImaginAb.